Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study
Table 2
30-day clinical outcomes.
Variable
Before PSM
After PSM
Bivalirudin (9)
Heparin ()
value
Bivalirudin ()
Heparin ()
value
NACE
26 (3.0)
151 (5.0)
0.012
26 (3.0)
52 (6.0)
0.003
MACCE
15 (1.7)
76 (2.5)
0.175
15 (1.7)
29 (3.3)
0.033
Death
5 (0.6)
34 (1.1)
0.151
5 (0.6)
17 (2.0)
0.010
Nonfatal MI
0
1 (0)
1.000
0
1 (0)
1.000
Nonfatal stroke
3 (0.3)
4 (0.1)
0.395
3 (0.3)
2 (0.2)
1.000
uTLR
7 (0.8)
38 (1.3)
0.272
7 (0.8)
10 (1.2)
0.465
Bleeding
All bleedings
12 (1.4)
78 (2.6)
0.038
12 (1.4)
26 (3.0)
0.022
BARC 2, 3, and 5 bleedings
1 (0.1)
9 (0.3)
0.577
1 (0.1)
5 (0.6)
0.218
BARC 2 bleedings
1 (0.1)
8 (0.3)
0.694
1 (0.1)
4 (0.5)
0.374
BARC 3 and 5 bleeding
0
1 (0)
1.000
0
1 (0.1)
1.000
Stent thrombosis
2 (0.2)
2 (0.1)
0.218
2 (0.2)
1 (0.1)
1.000
Definite
0
2 (0.1)
1.000
0
1 (0.1)
1.000
Probable
2 (0.2)
0
0.050
2 (0.2)
0
0.500
NACE: net adverse clinical event; MACCE: major adverse cardiovascular and cerebral event; MI: myocardial infarction; uTLR: urgent target lesion revascularization; BARC: bleeding academic research consortium. Data are presented as count (%).
